Ultragenyx Pharmaceutical Inc. (RARE) has a negative trailing P/E of -4.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 37.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -24.85%, forward earnings yield 2.68%. PEG 0.19 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -11.3 | -0.20 | 5.87 | 20,927.48 | - |
| 2017 | -6.5 | -0.44 | 5.13 | 753.82 | - |
| 2018 | -11.0 | 0.25 | 3.55 | 42.03 | - |
| 2019 | -6.0 | -0.08 | 3.70 | 23.30 | - |
| 2020 | -45.1 | 0.79 | 7.30 | 31.08 | - |
| 2021 | -12.6 | -0.11 | 6.18 | 16.22 | - |
| 2022 | -4.6 | -0.09 | 9.19 | 8.92 | - |
| 2023 | -5.8 | 0.31 | 12.77 | 8.10 | - |
| 2024 | -6.7 | 0.28 | 14.92 | 6.80 | - |
| 2025 | -3.9 | 0.54 | -28.35 | 3.37 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-6.21 | $133K | $-245.87M | -184867.7% |
| 2017 | $-7.12 | $2.61M | $-302.14M | -11567.3% |
| 2018 | $-3.97 | $51.5M | $-197.61M | -383.7% |
| 2019 | $-7.12 | $103.71M | $-402.73M | -388.3% |
| 2020 | $-3.07 | $271.03M | $-186.57M | -68.8% |
| 2021 | $-6.70 | $351.41M | $-454.03M | -129.2% |
| 2022 | $-10.12 | $363.33M | $-707.42M | -194.7% |
| 2023 | $-8.25 | $434.25M | $-606.64M | -139.7% |
| 2024 | $-6.29 | $560.23M | $-569.18M | -101.6% |
| 2025 | $-5.83 | $673M | $-575M | -85.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.22 | $-4.86 – $-1.90 | $769.09M | $750.16M – $790.05M | 13 |
| 2027 | $-0.73 | $-5.93 – $11.12 | $1.02B | $716.3M – $1.49B | 12 |
| 2028 | $0.68 | $-2.41 – $2.83 | $1.28B | $1.28B – $1.28B | 11 |
| 2029 | $3.22 | $2.38 – $4.88 | $1.72B | $1.37B – $2.4B | 4 |
| 2030 | $5.58 | $4.12 – $8.46 | $2.22B | $1.77B – $3.1B | 4 |
